Table 5.
Pharmacokinetic parameters
| C max (ng/mL) | AUC last (ng•h/L) | AUC inf (ng•h/L) | T max (h) | t 1/2 (h) | |||
|---|---|---|---|---|---|---|---|
| Gefitinib | 250 mg | No. of patients | 12 | 12 | 11 | 12 | 11 |
| Median (range) | 250 (148‐802) | 3430 (1880‐9850) | 8270 (3190‐23 400) | 4.0 (3.8‐8) | 22.6 (13.3‐42.6) | ||
| Mean (SD) | 294 (181) | 3910 (2140) | 8700 (5430) | 4.6 (1.3) | 23.8 (8.6) |
| C max (nmol/L) | AUC last (nmol•h/L) | AUC inf (nmol•h/L) | T max (h) | t 1/2 (h) | |||
|---|---|---|---|---|---|---|---|
| Vorinostat | Level 1 (200 mg) | No. of patients | 3 | 3 | 3 | 3 | 3 |
| Median (range) | 615 (430‐762) | 2720 (1470‐2830) | 2830 (1500‐2960) | 2.0 (1.1‐4.0) | 1.8 (1.6‐7.5) | ||
| Mean (SD) | 602 (166) | 2340 (753) | 2430 (809) | 2.4 (1.5) | 3.6 (3.4) | ||
| Level 2 (300 mg) | No. of patients | 3 | 3 | 3 | 3 | 3 | |
| Median (range) | 643 (641‐699) | 2250 (2210‐2830) | 2260 (2240‐2950) | 4.0 (1.8‐4.0) | 1.3 (1.1‐2.1) | ||
| Mean (SD) | 661 (33) | 2430 (348) | 2480 (407) | 3.3 (1.3) | 1.5 (0.5) | ||
| Level 3 (400 mg) | No. of patients | 6 | 6 | 6 | 6 | 6 | |
| Median (range) | 944 (695‐1630) | 4250 (2960‐8610) | 4270 (3010‐8650) | 4.0 (0.9‐4.1) | 2.1 (0.8‐3.1) | ||
| Mean (SD) | 1010 (335) | 4790 (2040) | 4810 (2040) | 3.5 (1.3) | 2.0 (1.1) |